We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+7.64%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$6.56B
AUM Growth
+$19.4M
Cap. Flow
-$249M
Cap. Flow %
-3.79%
Top 10 Hldgs %
37.22%
Holding
183
New
22
Increased
65
Reduced
79
Closed
14

Top Buys

Rank Stock Value
1
DXCM icon
DexCom
DXCM
+$38.5M
2
SAGE
Sage Therapeutics
SAGE
+$22M
3
SIBN icon
SI-BONE Inc
SIBN
+$19.1M
4
STE icon
Steris
STE
+$16.6M
5
CLDX icon
Celldex Therapeutics
CLDX
+$15.6M

Top Sells

Rank Stock Value
1
AXNX
Axonics, Inc. Common Stock
AXNX
+$114M
2
ISRG icon
Intuitive Surgical
ISRG
+$56.6M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$51.2M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$28.6M
5
EVH icon
Evolent Health
EVH
+$28.5M

Sector Composition

Rank Sector Weight
1 Healthcare 99.12%
2 Industrials 0.77%
3 Technology 0.02%
4 Communication Services 0.02%
5 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IONS icon
1
Ionis Pharmaceuticals
IONS
$8.99B
$360M 5.49%
8,299,514
-414,473
-5% -$19.8M
ARGX icon
2
argenx
ARGX
$53.8B
$319M 4.87%
811,016
-58,192
-7% -$22.5M
NBIX icon
3
Neurocrine Biosciences
NBIX
$17.2B
$284M 4.32%
2,055,874
-374,626
-15% -$51.2M
VRTX icon
4
Vertex Pharmaceuticals
VRTX
$123B
$280M 4.26%
668,750
-67,640
-9% -$28.6M
ISRG icon
5
Intuitive Surgical
ISRG
$122B
$272M 4.15%
682,186
-149,855
-18% -$56.6M
BSX icon
6
Boston Scientific
BSX
$65.4B
$216M 3.29%
3,148,676
-21,927
-0.7% -$1.41M
ITCI
7
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$195M 2.98%
2,819,482
-246,918
-8% -$17M
MRNA icon
8
Moderna
MRNA
$24.5B
$182M 2.78%
1,711,089
-197,331
-10% -$19.9M
DXCM icon
9
DexCom
DXCM
$29.6B
$169M 2.58%
1,221,197
+306,604
+34% +$38.5M
RVMD icon
10
Revolution Medicines
RVMD
$39.6B
$164M 2.49%
5,073,600
-17,400
-0.3% -$516K
ABT icon
11
Abbott
ABT
$175B
$163M 2.49%
1,434,183
-101,473
-7% -$11.6M
SYK icon
12
Stryker
SYK
$123B
$161M 2.45%
449,340
-16,384
-4% -$5.51M
MGNX icon
13
MacroGenics
MGNX
$285M
$147M 2.24%
9,965,862
+12,549
+0.1% +$190K
ALNY icon
14
Alnylam Pharmaceuticals
ALNY
$35.7B
$137M 2.09%
918,284
+32,966
+4% +$5.5M
INCY icon
15
Incyte
INCY
$23.4B
$123M 1.87%
2,153,388
-3,331
-0.2% -$200K
CLDX icon
16
Celldex Therapeutics
CLDX
$2.77B
$117M 1.79%
2,796,615
+380,319
+16% +$15.6M
AGIO icon
17
Agios Pharmaceuticals
AGIO
$2.36B
$117M 1.79%
4,006,000
-5,000
-0.1% -$134K
EW icon
18
Edwards Lifesciences
EW
$49.4B
$105M 1.61%
1,103,136
+84,138
+8% +$7.07M
BDX icon
19
Becton Dickinson
BDX
$43.6B
$103M 1.57%
415,700
+27,632
+7% +$6.61M
ARVN icon
20
Arvinas
ARVN
$517M
$98.7M 1.51%
2,390,800
-116,931
-5% -$5.11M
MDT icon
21
Medtronic
MDT
$106B
$87.8M 1.34%
1,007,000
+36,228
+4% +$3.09M
SAGE
22
DELISTED
Sage Therapeutics
SAGE
$83.7M 1.28%
4,465,544
+952,193
+27% +$22M
EXAS
23
DELISTED
Exact Sciences
EXAS
$78.6M 1.2%
1,138,526
+90,740
+9% +$5.74M
UNH icon
24
UnitedHealth
UNH
$387B
$73.6M 1.12%
148,719
+10,567
+8% +$5.37M
TNDM icon
25
Tandem Diabetes Care
TNDM
$1.17B
$71.9M 1.1%
2,031,888
+39,571
+2% +$1.06M
1
2 3 4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q1 2024 Portfolio in Review

As of Q1 2024, Bellevue Group held 183 positions worth $6.56B, up 0.3% from $6.54B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Bellevue Group withdrew a net $249M in Q1 2024, closing 14 positions and reducing 79 holdings. Its most notable exit was Axonics, Inc. Common Stock, an estimated $114M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Industrials and Technology.

Against the trend, Bellevue Group opened a new position in Steris worth $16.5M.

  • Bellevue Group's largest Q1 2024 buy was Steris: 73,434 shares worth $16.5M.
  • Bellevue Group added most to DexCom in Q1 2024, an estimated $38.5M increase.
  • Bellevue Group's biggest Q1 2024 reduction was Intuitive Surgical, cutting an estimated $56.6M.
  • Bellevue Group fully exited Axonics, Inc. Common Stock in Q1 2024, selling an estimated $114M.
  • Bellevue Group's ten largest holdings make up 37% of its $6.56B portfolio in Q1 2024.
  • Bellevue Group opened 22 new positions and closed 14 in Q1 2024.
  • Bellevue Group's portfolio value rose 0.3% quarter-over-quarter to $6.56B.

Based on Bellevue Group's 13F filing for Q1 2024, filed 15 May 2024.